NY-THE-BODY-SHOP
Millions of young people are missing from public life. With the climate crisis, global conflict and generational inequalities running rampant, the inputs, perspectives and representation of youth are needed more than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220509005499/en/
Almost half the world's population is under 30. Yet, they make up only 2.6% of parliamentarians around the world**. The average age of a world leader is currently 62***. Of all the parliaments in the world, 37% do not have a single Member of Parliament (MP) under age 30** and less than 1% of these young MPs are women.
Young people have the right to be included in political decisions that affect them, however, numerous barriers prevent their participation. The Body Shop and the Office of the United Nations Secretary-General's Envoy on Youth are collaborating to change this through the global Be Seen Be Heard campaign, which seeks to create long-term structural changes to decision-making to be more inclusive of young people.
It is launched today with the release of a research piece titled ‘ Be Seen Be Heard: Understanding young people’s political participation’.
The research includes the largest-ever survey carried out by The Body Shop, covering 26 countries with 27,043 respondents. It found that 82% of people surveyed agree that political systems need drastic reform to be fit for the future.
Two in three people also agree that the age balance in politics is wrong, with 8 in 10 people of all ages believing the ideal voting age (the age when someone can first vote) is 16 to 18, despite that in most countries the voting age is 18 or over. A third of those under age 30 surveyed would consider running for office versus only a fifth of those over age 30. People across all age groups agree that more opportunities for younger people to have a say in policy development and/or change would make political systems better.
David Boynton, CEO of The Body Shop says, “Our position is clear. The world’s problems cannot be solved by the same people making the same choices. The majority of young people are positive about the future, and we need to hear their views and ideas inside the halls of power. We will use our global reach to galvanise awareness and support, as we have in the past.”
Jayathma Wickramanayake, the United Nations Secretary-General’s Envoy on Youth says, “The intergenerational gap in power, influence and trust constitutes one of the biggest challenges of our time. Participation is a right, and a lack of youth representation where decisions are made contributes to a growing mistrust towards political institutions and a sense of alienation from elected leaders, caused by policies that do not reflect the priorities of youth, mirror their concerns or speak their language. This campaign is an opportunity to change that.”
The report suggests that young people’s participation in public decision-making could be improved long-term by a number of initiatives including; lowering voting ages, increasing formal youth representation, removing barriers for young people to participate in public decision-making, simplifying registration for first-time voters and improving young people’s leadership skills.
The campaign is launching globally in May 2022 and will run until mid-2025, driven by action in over 2,600 Body Shop stores in 75 countries, across six continents.
More information here.
Ends
** https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation
*** REIGN Dataset | REIGN (oefdatascience.github.io)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005499/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
